drugset / Trial / NCT07203391
Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis
NaSingle-groupOpen-labelTreatment
Summary
This is a combination study of Tebentafusp and the PI3Kdelta inhibitor, Roginolisib
Timeline
- Start
- 2026-02-01
- Primary completion
- 2027-12-01
- Completion
- 2029-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | roginolisib | Small molecule | 40 mg | — |
| Subject | roginolisib | Small molecule | 80 mg | — |